Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis

CONCLUSION: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.PMID:38435412 | PMC:PMC10907062 | DOI:10.1093/rap/rkae018

Source: Adv Data - March 4, 2024 Category: Epidemiology Authors: Jake Weddell Naw Ra Aung Din Stephanie R Harrison Xabier Michelena Dennis McGonagle Andrew Barr Claire Vandevelde Jane Freeston Helena Marzo-Ortega Source Type: research